Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Academic Article uri icon


  • Clinical observations reveal that an augmented pace of T-cell recovery after chemotherapy correlates with improved tumor-free survival, suggesting the add-back of T cells after chemotherapy may improve outcomes. To evaluate adoptive immunotherapy treatment for B-lineage non-Hodgkin lymphoma (NHL), we expanded T cells from client-owned canines diagnosed with NHL on artificial antigen presenting cells (aAPC) in the presence of human interleukin (IL)-2 and IL-21. Graded doses of autologous T cells were infused after CHOP chemotherapy and persisted for 49 days, homed to tumor, and significantly improved survival. Serum thymidine kinase changes predicted T-cell engraftment, while anti-tumor effects correlated with neutrophil-to-lymphocyte ratios and granzyme B expression in manufactured T cells. Therefore, chemotherapy can be used to modulate infused T-cell responses to enhance anti-tumor effects. The companion canine model has translational implications for human immunotherapy which can be readily exploited since clinical-grade canine and human T cells are propagated using identical approaches.

published proceedings

  • Sci Rep

altmetric score

  • 11.7

author list (cited authors)

  • O'Connor, C. M., Sheppard, S., Hartline, C. A., Huls, H., Johnson, M., Palla, S. L., ... Cooper, L.

citation count

  • 54

complete list of authors

  • O'Connor, Colleen M||Sheppard, Sabina||Hartline, Cassie A||Huls, Helen||Johnson, Mark||Palla, Shana L||Maiti, Sourindra||Ma, Wencai||Davis, R Eric||Craig, Suzanne||Lee, Dean A||Champlin, Richard||Wilson, Heather||Cooper, Laurence JN

publication date

  • April 2012